Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + dacarbazine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Lenalidomide + dacarbazine** is an investigational combination therapy composed of two drugs: lenalidomide, a thalidomide derivative with immunomodulatory, anti-angiogenic, and antineoplastic activity, and dacarbazine, an alkylating agent that induces cancer cell death by causing DNA breaks. Lenalidomide modulates the immune system by enhancing anti-inflammatory cell populations and natural killer cell cytotoxicity, while inhibiting pro-inflammatory cytokines and altering transcription factors through degradation of IKZF1, IKZF3, and CK1α. Dacarbazine is a cytotoxic agent that works by alkylating DNA, leading to apoptosis in rapidly dividing cancer cells. This combination has primarily been investigated in phase I/II trials for metastatic malignant melanoma and other cancers, aiming to improve antitumor efficacy over single-agent treatments.
- Brand names
- Lenalidomide AccordLenalidomide KrkaLenalidomide Mylan
- Other names
- lenalidomide + DTIClenalidomide + dacarbazine
02
Targets
DNACK1α (Casein kinase I alpha)IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)
Beyond the preview
Go deeper on lenalidomide + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + dacarbazine.